Logo image of GLUE

MONTE ROSA THERAPEUTICS INC (GLUE) Stock Fundamental Analysis

NASDAQ:GLUE - US61225M1027 - Common Stock

4.94 USD
+0.03 (+0.61%)
Last: 9/5/2025, 8:18:36 PM
4.94 USD
0 (0%)
After Hours: 9/5/2025, 8:18:36 PM
Fundamental Rating

5

GLUE gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 542 industry peers in the Biotechnology industry. While GLUE has a great health rating, its profitability is only average at the moment. GLUE has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

GLUE had positive earnings in the past year.
GLUE had a positive operating cash flow in the past year.
GLUE had negative earnings in each of the past 5 years.
GLUE had negative operating cash flow in 4 of the past 5 years.
GLUE Yearly Net Income VS EBIT VS OCF VS FCFGLUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

GLUE has a better Return On Assets (6.72%) than 91.70% of its industry peers.
The Return On Equity of GLUE (9.02%) is better than 92.80% of its industry peers.
GLUE's Return On Invested Capital of 3.72% is amongst the best of the industry. GLUE outperforms 91.51% of its industry peers.
Industry RankSector Rank
ROA 6.72%
ROE 9.02%
ROIC 3.72%
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
GLUE Yearly ROA, ROE, ROICGLUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

Looking at the Profit Margin, with a value of 13.58%, GLUE belongs to the top of the industry, outperforming 92.99% of the companies in the same industry.
GLUE has a better Operating Margin (8.40%) than 91.51% of its industry peers.
Industry RankSector Rank
OM 8.4%
PM (TTM) 13.58%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLUE Yearly Profit, Operating, Gross MarginsGLUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

More info and screens

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), GLUE is destroying value.
GLUE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for GLUE has been increased compared to 5 years ago.
GLUE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GLUE Yearly Shares OutstandingGLUE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
GLUE Yearly Total Debt VS Total AssetsGLUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 1.91 indicates that GLUE is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of GLUE (1.91) is better than 67.90% of its industry peers.
There is no outstanding debt for GLUE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 1.91
ROIC/WACC0.38
WACC9.8%
GLUE Yearly LT Debt VS Equity VS FCFGLUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 7.16 indicates that GLUE has no problem at all paying its short term obligations.
GLUE's Current ratio of 7.16 is fine compared to the rest of the industry. GLUE outperforms 69.93% of its industry peers.
GLUE has a Quick Ratio of 7.16. This indicates that GLUE is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of GLUE (7.16) is better than 70.48% of its industry peers.
Industry RankSector Rank
Current Ratio 7.16
Quick Ratio 7.16
GLUE Yearly Current Assets VS Current LiabilitesGLUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 115.63% over the past year.
Looking at the last year, GLUE shows a very strong growth in Revenue. The Revenue has grown by 2990.57%.
EPS 1Y (TTM)115.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.12%
Revenue 1Y (TTM)2990.57%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%394.01%

3.2 Future

GLUE is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -6.65% yearly.
GLUE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.64% yearly.
EPS Next Y78.74%
EPS Next 2Y-18.5%
EPS Next 3Y-9.38%
EPS Next 5Y-6.65%
Revenue Next Year431.03%
Revenue Next 2Y40.14%
Revenue Next 3Y33.49%
Revenue Next 5Y22.64%

3.3 Evolution

GLUE Yearly Revenue VS EstimatesGLUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
GLUE Yearly EPS VS EstimatesGLUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 14.11, GLUE is valued correctly.
Based on the Price/Earnings ratio, GLUE is valued cheaper than 95.94% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.06. GLUE is valued slightly cheaper when compared to this.
GLUE is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 14.11
Fwd PE N/A
GLUE Price Earnings VS Forward Price EarningsGLUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, GLUE is valued cheaply inside the industry as 97.23% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 12.79
EV/EBITDA -8.95
GLUE Per share dataGLUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

GLUE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A cheap valuation may be justified as GLUE's earnings are expected to decrease with -9.38% in the coming years.
PEG (NY)0.18
PEG (5Y)N/A
EPS Next 2Y-18.5%
EPS Next 3Y-9.38%

More info and screens

0

5. Dividend

5.1 Amount

GLUE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MONTE ROSA THERAPEUTICS INC

NASDAQ:GLUE (9/5/2025, 8:18:36 PM)

After market: 4.94 0 (0%)

4.94

+0.03 (+0.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners101.37%
Inst Owner Change-6.27%
Ins Owners0.85%
Ins Owner Change0.06%
Market Cap305.09M
Analysts84
Price Target16.61 (236.23%)
Short Float %13.59%
Short Ratio19.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)162.39%
Min EPS beat(2)61.87%
Max EPS beat(2)262.91%
EPS beat(4)4
Avg EPS beat(4)361.68%
Min EPS beat(4)41.55%
Max EPS beat(4)1080.39%
EPS beat(8)7
Avg EPS beat(8)176.66%
EPS beat(12)11
Avg EPS beat(12)118.84%
EPS beat(16)13
Avg EPS beat(16)84.29%
Revenue beat(2)2
Avg Revenue beat(2)277.73%
Min Revenue beat(2)110.55%
Max Revenue beat(2)444.91%
Revenue beat(4)4
Avg Revenue beat(4)305.64%
Min Revenue beat(4)110.55%
Max Revenue beat(4)444.91%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.74%
EPS NQ rev (1m)14.78%
EPS NQ rev (3m)13.24%
EPS NY rev (1m)62.23%
EPS NY rev (3m)82.96%
Revenue NQ rev (1m)-8.31%
Revenue NQ rev (3m)478.47%
Revenue NY rev (1m)23.31%
Revenue NY rev (3m)105.64%
Valuation
Industry RankSector Rank
PE 14.11
Fwd PE N/A
P/S 1.71
P/FCF 12.79
P/OCF 11.01
P/B 1.14
P/tB 1.14
EV/EBITDA -8.95
EPS(TTM)0.35
EY7.09%
EPS(NY)-1.43
Fwd EYN/A
FCF(TTM)0.39
FCFY7.82%
OCF(TTM)0.45
OCFY9.08%
SpS2.88
BVpS4.34
TBVpS4.34
PEG (NY)0.18
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 6.72%
ROE 9.02%
ROCE 4.71%
ROIC 3.72%
ROICexc 43.54%
ROICexgc 43.54%
OM 8.4%
PM (TTM) 13.58%
GM N/A
FCFM 13.4%
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 46.35%
Cap/Sales 2.17%
Interest Coverage 250
Cash Conversion 118.97%
Profit Quality 98.69%
Current Ratio 7.16
Quick Ratio 7.16
Altman-Z 1.91
F-Score8
WACC9.8%
ROIC/WACC0.38
Cap/Depr(3y)233.13%
Cap/Depr(5y)356.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)115.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.12%
EPS Next Y78.74%
EPS Next 2Y-18.5%
EPS Next 3Y-9.38%
EPS Next 5Y-6.65%
Revenue 1Y (TTM)2990.57%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%394.01%
Revenue Next Year431.03%
Revenue Next 2Y40.14%
Revenue Next 3Y33.49%
Revenue Next 5Y22.64%
EBIT growth 1Y110.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.61%
EBIT Next 3Y8.63%
EBIT Next 5YN/A
FCF growth 1Y120.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y129.71%
OCF growth 3YN/A
OCF growth 5YN/A